Core Viewpoint - The company has updated its share buyback plan, indicating confidence in its long-term growth and market performance, as the current stock price is perceived to be below its true value [1] Group 1: Share Buyback Plan - The updated share buyback plan allows the company to repurchase up to 25,461,295 shares over a period of 50 trading days starting from November 13, 2025 [1] - The total shares to be repurchased, including those already bought back in 2025, will represent 5% of the total issued shares as of the authorization date [1] Group 2: Management Confidence - The board believes that the share buyback plan reflects the confidence of the directors and senior management in the company's long-term growth and market performance [1] - The board asserts that the buyback plan is in the best interest of the company and its shareholders [1] Group 3: Shareholder Activity - The company has been informed that Yijie Biotechnology Holdings Limited and its concert parties have cumulatively purchased 100,000 shares between November 6 and November 10, 2025 [1] - Following this purchase, the concert group holds a total of 218,048,730 shares, representing approximately 37.92% of the total issued shares (excluding treasury shares) [1] - The board views this increase in shareholding as a sign of confidence from major shareholders regarding the company's prospects and growth potential [1]

Core Viewpoint - The company has updated its share buyback plan to repurchase up to 25,461,295 shares over a period of 50 trading days starting from November 13, 2025, indicating confidence in its long-term growth and market performance [1] Group 1: Share Buyback Plan - The updated share buyback plan represents 5% of the total issued shares as of the authorization date in 2025 [1] - The board believes the current share price does not reflect the company's true value and business prospects [1] - The buyback plan is seen as being in the best interest of the company and its shareholders [1] Group 2: Shareholding Update - The company has been informed that Yijie Biotechnology Holdings Limited and its concert parties have cumulatively purchased 100,000 shares between November 6 and November 10, 2025 [1] - Following this acquisition, the Yijie concert group holds 218,048,730 shares, representing approximately 37.92% of the total issued shares (excluding treasury shares) as of the announcement date [1]

Core Viewpoint - 科济药业-B (02171.HK) has announced an updated share repurchase plan, indicating a strategic move to enhance shareholder value through the buyback of shares [1] Group 1: Share Repurchase Details - Starting from November 13, 2025, the company plans to repurchase up to approximately 25.46 million shares within 50 trading days on the open market [1] - The total shares to be repurchased, including the approximately 3.31 million shares already bought back, will represent 5% of the total issued shares as of the authorization date for the 2025 share repurchase [1]

Group 1 - The company Kintor Pharmaceutical (02171) has updated its share buyback plan to repurchase up to 25,461,295 shares within 50 trading days starting from November 13, 2025 [1] - The updated buyback plan represents 5% of the total issued shares as of the authorization date in 2025, including shares already repurchased in 2025 [1] - The board believes that the current share price is below its true value and does not adequately reflect the company's business prospects, indicating confidence in long-term growth and market performance [1] Group 2 - The board has been informed that Eucure Biopharma and its concert parties have cumulatively purchased 100,000 shares between November 6 and November 10, 2025 [1] - Following this acquisition, Eucure and its concert parties hold a total of 218,048,730 shares, representing approximately 37.92% of the total issued shares as of the announcement date, excluding treasury shares [1]

自願公告 本公司購回股份及主要股東增持股份 香港交易及結算所有限公司、香港聯合交易所有限公司及香港中央結算有限公司對本公告的內 容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任 何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 CARsgen Therapeutics Holdings Limited 科濟藥業控股有限公司 （於開曼群島註冊成立的有限公司） （股份代號：2171） 本公告由科濟藥業控股有限公司（「本公司」，連同其附屬公司及併表聯屬實體統 稱「本集團」或「科濟藥業」）自願作出。 本公司購回股份 茲提述(1)本公司日期為2025年5月13日的自願公告，內容有關股份購回計劃（「過 往股份購回計劃」），即自2025年5月8日起的150個香港交易日內在公開市場上購 回不超過本公司股份（「股份」）1%的股份；及(2)本公司股東於2025年5月22日舉 行的股東週年大會上授予的股份購回一般授權，據此最多可購回於有關決議案獲 通過之日已發行股份總數之10%，即最多57,543,590股股份（「2025年股份購回授 權」）。自2025年10月起，本公司已根據202 ...

Core Viewpoint - Company Kintor Pharmaceutical (科济药业-B) announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company will spend HKD 4.0473 million to repurchase 245,000 shares [1]

Core Viewpoint - Kintor Pharmaceutical Co., Ltd. announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Company Summary - Kintor Pharmaceutical plans to repurchase 245,000 shares at a total cost of HKD 4.0473 million [1]

Group 1 - The company Kintor Pharmaceutical-B (02171.HK) announced a share buyback on November 11, spending HKD 4.047 million to repurchase 245,000 shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 科濟藥業控股有限公司 呈交日期： 2025年11月11日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02171 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有 ...

Core Viewpoint - Non-executive director Guo Huaqing increased his stake in Kexing Pharmaceutical-B (02171) by purchasing 30,000 shares at a price of HKD 16.4 per share, totaling HKD 492,000, which reflects confidence in the company's future prospects [1] Summary by Category - **Share Purchase Details** - Guo Huaqing acquired 30,000 shares at a price of HKD 16.4 each, amounting to a total investment of HKD 492,000 [1] - **Post-Purchase Holdings** - Following the purchase, Guo Huaqing's total shareholding in Kexing Pharmaceutical-B increased to approximately 218 million shares, representing a 37.73% ownership stake [1]